News | April 17, 2026
NIFTY Pharma shows stable trend amid cautious market sentiment
Muted movement reflects consolidation phase as investors await earnings triggers
Muted movement reflects consolidation phase as investors await earnings triggers
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
Subscribe To Our Newsletter & Stay Updated
